Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

erance costs and $11 million for merger costs) and $94 million ($77 million for severance costs and $17 million for integration-related costs), respectively. For the six months ended June 30, 2009 and 2008 these charges were $104 million ($74 million for severance costs and $30 million for merger costs) and $117 million ($84 million for severance costs and $33 million for integration-related costs), respectively. 3/ Included in Equity income for the three and six months ended June 30, 2008 was $64 million of income related to the termination of a respiratory joint venture with Merck. 4/ Diluted EPS for the three months ended June 30, 2009 is calculated based on net income available to common shareholders and average diluted shares - common and participating - outstanding. For the three months ended June 30, 2009, approximately 91 million common shares obtainable upon conversion of Schering-Plough's 2007 mandatory convertible preferred stock were excluded from the computation of diluted EPS because their effect would have been antidilutive. For the six months ended June 30, 2009, diluted EPS is calculated based on net income and average diluted shares - common and participating - outstanding. For the six months ended June 30, 2009, approximately 91 million common shares obtainable upon conversion of Schering-Plough's 2007 mandatory convertible preferred stock were included in the computation of diluted EPS because their effect would have been dilutive.


    SCHERING-PLOUGH CORPORATION

    Reconciliation from Reported Net Income Available to Common Shareholders
    and Reported Diluted Earnings Per Common Share to As Reconciled Amounts
    for Net Income Available to Common Shareholders and Diluted Earnings per
    Common Share
    (Amounts in Millions, except per share figures)

    To supplement its consolidated
'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Topical BioMedics, Inc., is celebrating 20 ... their suffering, restoring hope an quality of life and ... possible because of the innovative cellular biomedicines research that ... reality. , The company was founded in 1994 ... (president, chief of research, and Topricin inventor), Aurora Paradise ...
(Date:9/22/2014)... Pa. (PRWEB) September 22, 2014 ... rapid diagnostics for the food and beverage industries, ... will be distributed under a non-exclusive agreement by ... and services. , Enartis, an Esseco Group company ... to winemakers in California and other global markets ...
(Date:9/22/2014)... N.J. , Sept. 22, 2014  WIRB-Copernicus ... and ethical review services for clinical research, announced ... (WIRB) has been reaccredited by the Association ... (AAHRPP), which endeavors to improve safeguards for clinical ... Donald A. Deieso , Ph.D., commented, "It ...
(Date:9/22/2014)... BETHESDA, Md. , Sept. 22, 2014  Spherix Incorporated ... fostering and monetization of intellectual property, today announced that the ... patent to the Company in the month of September that ... The issued patent is: USRE45,121 , ... 2014 , Filing date: Dec 27, 2012 ...
Breaking Biology Technology:Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3
... Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS;, ... next,generation of monoclonal antibodies based on its Dynamic ... and Chairman, will,present at the 7th Annual BIO ... Morhet,s thirty-minute presentation to potential investors and,industry partners ...
... Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET), NOVATO, Calif., Oct. 28 , ... Q3 2008 ... 190.5% increase Naglazyme Net Product Revenue ... Aldurazyme Net Sales by Genzyme $38.2 ...
... ASA (OSL:DIAG),today announced that it has signed ... panEuropean provider of gene expression-based,diagnostic testing and ... marking scheduled in early2009, DiaGenic will be ... Europe its innovative blood-based,gene-expression diagnostic test for ...
Cached Biology Technology:InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum 2BioMarin Announces Third Quarter 2008 Financial Results 2BioMarin Announces Third Quarter 2008 Financial Results 3BioMarin Announces Third Quarter 2008 Financial Results 4BioMarin Announces Third Quarter 2008 Financial Results 5BioMarin Announces Third Quarter 2008 Financial Results 6BioMarin Announces Third Quarter 2008 Financial Results 7BioMarin Announces Third Quarter 2008 Financial Results 8BioMarin Announces Third Quarter 2008 Financial Results 9BioMarin Announces Third Quarter 2008 Financial Results 10BioMarin Announces Third Quarter 2008 Financial Results 11BioMarin Announces Third Quarter 2008 Financial Results 12Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests 2
(Date:9/22/2014)... In 2011 the Society of Environmental Toxicology and ... to identify and prioritize the scientific research needed to ... (PPCPs) in the environment. The effort was extended, ... of the Society,s international journal, Integrated Environmental Assessment ... accompanied by a podcast interviewing the lead author of ...
(Date:9/22/2014)... 22, 2014)The Brain & Behavior Research Foundation ... NARSAD Young Investigator Grants valued at more ... world,s most promising young scientists. Recipients of ... research will seek to identify causes, improve ... disorders that affect one in four people, ...
(Date:9/22/2014)... 22, 2014) Additive manufacturing (AM), or 3D ... production of complex-shaped metal components strong enough for ... errors and distortions, as well as quality standards ... pace with the technology. Engineers at the University ... to develop enhanced modeling and simulation (M&S) technology ...
Breaking Biology News(10 mins):Priorities for research on pharmaceutical and personal care products in the environment 2Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2Pitt engineers receive grants to enhance additive manufacturing 2Pitt engineers receive grants to enhance additive manufacturing 3
... 30, 2013 /PRNewswire-iReach/ -- Clinilabs, a contract research organization ... to industry, announced today that they have begun a ... for Type 2 Diabetes Mellitus.  The study is being ... daily doses of the investigational medication over periods of ...
... the University of Wisconsin-Madison have made a discovery that, ... may contribute to diseases like Alzheimer,s and Parkinson,s, which ... the brain. With proteins, shape is everything. The ... molecules about a cell, others to provide essential cellular ...
... laboratory work allowed a diverse team of University of Pittsburgh ... Nature Cell Biology that they had solved the mystery ... By discovering a mechanism by which mitochondria tiny structures ... they are damaged and need to be eliminated, the Pitt ...
Cached Biology News:Leading Pharma Company Selects Clinilabs to Conduct a Phase 1 Study of an Investigational Type 2 Diabetes Medication 2Zinc, proteins, and an essential cellular balancing act 2When cells 'eat' their own power plants; Pitt scientists solve mystery of cellular process 2When cells 'eat' their own power plants; Pitt scientists solve mystery of cellular process 3
... The FastPlax Antibody is used to detect ... the surface of infected cells as early ... basis of the FastPlax Titer Kit, which ... 25-48 hours. The FastPlax Antibody ...
Alexa Fluor 647 anti-mouse IL-12 (Interleukin-12) / IL-23 (Interleukin-23) p40 25 ug...
PKC (pSer345), phospho-specific...
PE Rat anti-Hu CD267 Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: